| PE25.11 | Mapping HIV prevention product preferences among adolescent girls and young women at high risk of HIV: results from a discrete choice experiment in South Africa | E-poster | Product acceptability and adherence |
| PU25.02 | Correlates of adherence to the dapivirine vaginal ring for HIV-1 prevention | Publication Only | Product acceptability and adherence |
| PU25.03 | Health care providers' preferences about an MPT implant: insights from South Africa and Zimbabwe on the Subcutaneous Contraceptive HIV Implant Engineered for Long-acting Delivery (SCHIELD) Study | Publication Only | Product acceptability and adherence |
| OA04.02 | High protection against vaginal SHIV infection in macaques by a biodegradable implant releasing tenofovir alafenamide | Oral Abstract Session | Preclinical studies for HIV prevention |
| OA18.04 | Heterologous prime boost immunisations with improved DNA, MVA and protein HIV-1 subtype C vaccines elicit Tier 2 neutralising antibodies in a Chinese rhesus monkey model | Oral Abstract Session | Preclinical studies for HIV prevention |
| OA20.03 | Immune perturbation is more profound in newborn than in infant macaques during acute SHIV infection | Oral Abstract Session | Preclinical studies for HIV prevention |
| PE24.01 | Efficacy of a vaginal ring containing the gp120 blocker DS003 in pigtailed macaques | E-poster | Preclinical studies for HIV prevention |
| PE24.02 | Transport and permeability properties of dapivirine: understanding potential drug-drug interactions | E-poster | Preclinical studies for HIV prevention |
| PE24.04LB | Dose response to tenofovir disoproxil fumarate and tenofovir released via intravaginal ring in the sheep vaginal safety and pharmacokinetics model | E-poster | Preclinical studies for HIV prevention |
| PE24.05LB | Induction of neutralization breadth and broadly neutralizing antibody lineage responses in HIV envelope BG505 SOSIP immunized infant macaques | E-poster | Preclinical studies for HIV prevention |